General Information of Drug (ID: DMTY6OF)

Drug Name
ATI-501 Drug Info
Indication
Disease Entry ICD 11 Status REF
Alopecia ED70 Phase 2 [1]
Cross-matching ID
PubChem CID
23585272
TTD Drug ID
DMTY6OF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Janus kinase 3 (JAK-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [3]
Ritlecitinib DMYKNME Alopecia areata ED70.2 Approved [4]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [5]
VX-509 DM2U3MX Rheumatoid arthritis FA20 Phase 2/3 [6]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [4]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [7]
TD-8236 DMTOMJN Asthma CA23 Phase 2 [8]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [9]
SNA-125 DM8L1GJ Atopic dermatitis EA80 Phase 1 [4]
GDC-0214 DMCNSII Asthma CA23 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Janus kinase 1 (JAK-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [6]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [11]
Upadacitinib DM32B5U Rheumatoid arthritis FA20 Approved [12]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [13]
SHR0302 DMUL8ZT Ulcerative colitis DD71 Phase 3 [14]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [4]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [15]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [13]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [4]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [2]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03594227) ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
6 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
7 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
9 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
10 Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789.
11 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
14 Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)